### Analysis of Selection Pressures on rs113488022

The variant **rs113488022** is located in the **BRAF** gene, which is well-known for its role in cell signaling pathways, particularly the MAPK/ERK pathway. Variants in this gene, including rs113488022, are often associated with various cancers and developmental syndromes. Below is an analysis of the selection pressures that may have acted on this variant over time:

---

### 1. **Variant Identification**
- **rs Number**: [rs113488022](https://identifiers.org/dbsnp/rs113488022)
- **Gene**: BRAF
- **Chromosome**: 7
- **Position**: 140753336
- **HGVS Notations**:
  - Genomic: `chr7:g.140753336A>C`, `chr7:g.140753336A>G`, `chr7:g.140753336A>T`
  - Protein: Multiple changes depending on the transcript, including **p.Val600Gly**, **p.Val600Ala**, and **p.Val600Glu**.
- **TogoVar Link**: [TogoVar rs113488022](https://togovar.org/variant/rs113488022)

---

### 2. **Disease Associations**
The variant is strongly associated with several diseases, particularly cancers:
- **Pathogenic (P)**: Melanoma, RASopathy, Papillary thyroid carcinoma, Non-small cell lung carcinoma, and others.
- **Likely Pathogenic (LP)**: Multiple myeloma, Glioblastoma, and others.
- **Neutral or Uncertain (NP/US)**: Cardio-facio-cutaneous syndrome, Squamous cell carcinoma of colon, and others.

The strong association with cancers suggests that this variant may have undergone **positive selection** in somatic cells due to its role in promoting cell proliferation and survival, which are advantageous for tumor growth.

---

### 3. **Allele Frequency Comparison**
- **Global Frequency**: Extremely rare in the general population, with an allele frequency of **1.37 × 10⁻⁶** in the gnomAD exomes dataset.
- **Japanese Population**: No specific allele frequency data for Japanese populations is available in the retrieved dataset.

The rarity of this variant in the general population suggests that it is under **purifying selection** in the germline, as it likely has deleterious effects on fitness when inherited.

---

### 4. **Functional Impact**
- **SIFT**: 0.0 (deleterious)
- **PolyPhen**: Ranges from 0.294 to 0.958 (probably damaging)
- **AlphaMissense**: 0.9773–0.9927 (high pathogenicity)

The functional predictions indicate that this variant has a strong negative impact on protein function, which aligns with its association with severe diseases. This supports the hypothesis of **purifying selection** acting on the germline to remove the variant from the population.

---

### 5. **Selection Pressures**
#### a. **Purifying Selection**
- The variant is extremely rare in the general population, indicating that it is likely removed from the gene pool due to its deleterious effects on fitness.
- Germline transmission of this variant is likely selected against because of its association with severe developmental syndromes and cancers.

#### b. **Positive Selection in Somatic Cells**
- In somatic cells, the variant is positively selected in the context of cancer. The **p.Val600Glu** (V600E) mutation, for example, is a well-known driver mutation in melanoma and other cancers. It confers a growth advantage to cells by constitutively activating the MAPK/ERK pathway.

#### c. **Balancing Selection**
- There is no evidence to suggest balancing selection for this variant, as it is not common in any population and does not appear to confer any known fitness advantage in non-disease contexts.

---

### 6. **Evolutionary Implications**
- The variant likely arose as a **de novo mutation** in somatic cells, where it is positively selected in cancers.
- In the germline, the variant is under **strong purifying selection**, preventing its spread in the population.
- The dual role of this variant—deleterious in the germline but advantageous in somatic cells—illustrates the complex interplay of selection pressures in different biological contexts.

---

### Conclusion
The variant **rs113488022** has been shaped by **purifying selection** in the germline due to its deleterious effects on fitness, while undergoing **positive selection** in somatic cells due to its role in cancer progression. This duality highlights the importance of context in understanding selection pressures.

---

### 日本語での説明

#### 選択圧の分析
**rs113488022**は、細胞シグナル伝達経路（特にMAPK/ERK経路）に関与する**BRAF**遺伝子に位置する変異です。この変異は、がんや発達障害と強く関連しており、以下のような選択圧が作用していると考えられます。

---

#### 1. 変異の特定
- **rs番号**: [rs113488022](https://identifiers.org/dbsnp/rs113488022)
- **遺伝子**: BRAF
- **染色体**: 7
- **位置**: 140753336
- **HGVS表記**:
  - ゲノム: `chr7:g.140753336A>C`, `chr7:g.140753336A>G`, `chr7:g.140753336A>T`
  - タンパク質: **p.Val600Gly**, **p.Val600Ala**, **p.Val600Glu**など
- **TogoVarリンク**: [TogoVar rs113488022](https://togovar.org/variant/rs113488022)

---

#### 2. 疾患との関連
この変異は、特にがんと強く関連しています。
- **病原性 (P)**: メラノーマ、RASopathy、乳頭状甲状腺がん、非小細胞肺がんなど
- **病原性の可能性が高い (LP)**: 多発性骨髄腫、神経膠芽腫など
- **中立または不明 (NP/US)**: 心臓顔面皮膚症候群、大腸扁平上皮がんなど

これらの関連性は、この変異が体細胞でのがん進行において**正の選択圧**を受けている可能性を示唆しています。

---

#### 3. アレル頻度の比較
- **全体の頻度**: gnomADデータセットでは非常に稀で、アレル頻度は**1.37 × 10⁻⁶**。
- **日本人集団**: 日本人集団における具体的な頻度データは取得できませんでした。

この変異が一般集団で非常に稀であることは、**浄化選択**（有害な変異を排除する選択圧）が働いていることを示唆しています。

---

#### 4. 機能的影響
- **SIFT**: 0.0（有害）
- **PolyPhen**: 0.294～0.958（おそらく有害）
- **AlphaMissense**: 0.9773～0.9927（高い病原性）

これらの予測は、この変異がタンパク質機能に強い負の影響を与えることを示しており、浄化選択の仮説を支持します。

---

#### 5. 選択圧
##### a. 浄化選択
- この変異は一般集団で非常に稀であり、遺伝的適応度に対する有害な影響のため、遺伝子プールから排除されている可能性があります。

##### b. 体細胞での正の選択
- 体細胞では、この変異はがんにおいて正の選択を受けています。例えば、**p.Val600Glu**（V600E）変異は、メラノーマや他のがんでよく知られたドライバー変異です。

##### c. 均衡選択
- この変異が非疾患コンテキストで適応的な利点を持つという証拠はなく、均衡選択の可能性は低いです。

---

#### 6. 進化的影響
- この変異は、体細胞での**新規変異**として発生し、がんにおいて正の選択を受けている可能性があります。
- 一方で、胚系では**強い浄化選択**を受けており、集団内での広がりが抑制されています。

---

#### 結論
**rs113488022**は、胚系では**浄化選択**を受けている一方で、体細胞ではがん進行において**正の選択**を受けています。この二重性は、異なる生物学的コンテキストにおける選択圧の重要性を示しています。

